NEURINOX
NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies
| Coordinatore | UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Sito del progetto | http://www.neurinox.eu/ |
| Totale costo | 17˙041˙709 € |
| EC contributo | 11˙425˙095 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | coordinator | 1˙462˙676.00 |
| 2 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 1˙983˙090.00 |
| 3 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | participant | 1˙191˙300.00 |
| 4 |
GENKYOTEX INNOVATION SAS
Organization address
address: DOMAINE DE CHOSAL contact info |
FR (ARCHAMPS) | participant | 1˙129˙402.00 |
| 5 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 1˙086˙940.00 |
| 6 |
UNIVERSITE JOSEPH FOURIER GRENOBLE 1
Organization address
address: "Avenue Centrale, Domaine Universitaire 621" contact info |
FR (GRENOBLE) | participant | 944˙801.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 866˙670.00 |
| 8 |
Redoxis AB
Organization address
address: MEDICINAREGATAN 8A SAHLGRENSKA SCIENCE PARK contact info |
SE (GOTEBORG) | participant | 770˙800.00 |
| 9 |
SYNAPCELL SAS
Organization address
address: AVENUE DES JEUX OLYMPIQUES 1000 contact info |
FR (GRENOBLE) | participant | 683˙000.00 |
| 10 |
ARTTIC
Organization address
address: Rue du Dessous des Berges 58A contact info |
FR (PARIS) | participant | 554˙966.00 |
| 11 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 401˙450.00 |
| 12 |
NEURIX SA
Organization address
address: CHEMIN KERMELY 10 contact info |
CH (GENEVE) | participant | 350˙000.00 |
| 13 |
THE UNIVERSITY OF SYDNEY
Organization address
address: The University of Sydney contact info |
AU (SYDNEY) | participant | 0.00 |
| 14 |
VICTOR CHANG CARDIAC RESEARCH INSTITUTE LIMITED LBG
Organization address
address: LIVERPOOL STREET 405 contact info |
AU (DARLINGHURST) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'NEURINOX aims at elucidating the role of NADPH oxidases (NOX) in neuroinflammation and its progression to neurodegenerative diseases (ND), as well as evaluating the potential of novel ND therapeutics approaches targeting NOX activity. NOX generate reactive oxygen species (ROS) and have emerged as regulators of neuroinflammation. Their role is complex: ROS generated by NOX lead to tissue damage in microglia-mediated neuroinflammation, as seen in amyotrophic lateral sclerosis (ALS), while absence of ROS generation enhances the severity of autoimmune-mediated neuroinflammation, as seen for e.g. in multiple sclerosis (MS). The objective of the 5 years NEURINOX project is to understand how NOX controls neuroinflammation, identify novel molecular pathways and oxidative biomarkers involved in NOX-dependent neuroinflammation, and develop specific therapies based on NOX modulation. The scientific approach will be to: (i) identify NOX-dependent molecular mechanisms using dedicated ND animal models (ii) develop therapeutic small molecules either inhibiting or activating NOX and test their effects in animal models (iii) test the validity of identified molecular pathways in clinical studies in ALS and MS patients. NEURINOX will contribute to better understand brain dysfunction, and more particularly the link between neuroinflammation and ND and to identify new therapeutic targets for ND. A successful demonstration of the benefits of NOX modulating drugs in ALS and MS animal models, and in ALS early clinical trials will validate a novel high potential therapeutics target for ALS and also many types of ND. NEURINOX has hence a strong potential for more efficient ND healthcare for patients and thus for reducing ND healthcare costs. This multi-disciplinary consortium includes leading scientists in NOX research, ROS biology, drug development SMEs, experts in the neuroinflammatory aspects of ND, genomics and proteomics, and clinicians able to translate the basic science to the patient.'
Introduzione (Teaser)
Neurodegenerative diseases (NDs) represent a major health care problem, with current treatments addressing the symptoms rather than the cause. Identifying novel therapeutic targets of neuroinflammation will target multiple NDs as sustained inflammation is responsible for progressive neurodegeneration.